Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About Oyster Point Pharma, Inc.
Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. The company is headquartered in Princeton, New Jersey and currently employs 303 full-time employees. The company went IPO on 2019-10-31. The firm is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ophthalmic diseases. The firm's lead product candidate is TYRVAYA Nasal Spray, a nicotinic acetylcholine receptor (nAChR) agonist for the treatment of the signs and symptoms of dry eye disease. TYRVAYA Nasal Spray’s is a mechanism of action, which is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the trigeminal parasympathetic pathway (TPP) and stimulating the glands and cells responsible for natural tear film production. The company is sprayed into the anterior portion of the nasal cavity and stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.
Industry: Biological Products, (No Diagnostic Substances) Peers: Actinium Pharmaceuticals, Inc. Acumen Pharmaceuticals, Inc. Akouos, Inc. Armata Pharmaceuticals, Inc. ARDELYX, INC. LENZ Therapeutics, Inc. VBI Vaccines Inc/BC ARS Pharmaceuticals, Inc. Verastem, Inc.
